Industry's Voice

Hardman_Mike_AstraZeneca_150x110.png

Matthias Gottwald, Bayer Pharma

“Continuous professional development is of high importance for an innovative global pharmaceutical company. Especially in challenging times with a continuously changing environment for the development of new medicines employees are needed who are familiar with the most modern processes, tools and technologies. This is especially important in a highly regulated environment like medicines development. High quality, upto- date training is needed to develop the specific expertise in their respective function, but also to build broader competence when moving to a new position within the company. And it is also of high importance that all scientists have a basic understanding of the overall process of drug discovery and development, as a significant part of the work is done in multidisciplinary and multifunctional teams. Training is an integral element of the development plans, and the opportunity to make use of training programmes is highly appreciated by the colleagues. We offer a broad range of in-house trainings and rely on high quality training programmes like the ones recognised by PharmaTrain. Especially modular e-learning programs are of high value for a global organization; with limited logistical effort employees can participate in a training whenever they need it and wherever they are located. This is an area course providers should continuously improve.

_______________________________________________________________
Hardman_Mike_AstraZeneca_150x110.png

Mike Hardman, AstraZeneca

“The Pharmaceutical Industry recognized the need for greater competence
in integrated medicines development through high quality and standardised training throughout Europe – and thereby mastering the process.”

_______________________________________________________________
niese.jpg

Detlef Niese, formerly with Novartis

“The PharmaTrain project is built on a partnership between industry, academia and other professional bodies. It offers a unique opportunity for all of us in Europe to accellerate the process of developing more innovative, safer and more effective medicines – more economically. This is an opportunity we must not miss.”

_______________________________________________________________
Online training in Medicines Development has been recognised by our company almost a decade ago and we have helped to get Hibernia College going. Some of this early experience has paved the way towards creation of Introduction to Medicines Development which PharmaTrain plans to use in all its training programmes as well as a standalone (e1-compact, ECTS point in the PharmaTrain e-library).

Chan_Anthony_Pfizer_150x110.png

Anthony Chan, Pfizer

“Over the last few years, e-teaching technology has become more attractive and more interactive. All training will have some blending with online segment in the future.”

_______________________________________________________________